AMIVAS Ireland Ltd (AMIVAS), a biopharmaceutical company focused on developing, commercialising, manufacturing and distributing artesunate for the treatment of severe malaria, today announced the launch of Artesunate AMIVAS in Europe and the U.K.
PeptiGrowth Inc.has successfully developed a novel synthetic peptide called "FGF2 alternative peptide (FGFR1c agonist)", which has equivalent function to recombinant FGF2 (Fibroblast Growth Factor 2, basic FGF (bFGF)). This product will be on the market at the beginning of October 2024.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan® as approved by the U.S.
CVS Health® announced that CVS Pharmacy® locations in Massachusetts are now offering hormonal contraceptive prescribing services. Patients interested in receiving a birth control prescription can be evaluated by a CVS pharmacist and, if clinically eligible, receive a prescription for birth control.
MGI Tech Co., Ltd. a company committed to building core tools and technologies that drive innovation in life science, announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneSEQ-WY01*. With potential across different areas of genomics, CycloneSEQ™ technology integrates numerous technological improvements, including advanced protein engineering, a novel flow cell design, and a cutting-edge basecalling algorithm, to enable high accuracy and throughput in sequencing.